Publication at First Faculty of Medicine |
2012
Abstract
Pasireotid is a new somatostatin analog with strong binding to somatostatin receptors SSTR-2. Consequently it represents a new drug for treatment of pituitary adenomas secreting adrenocorticotropic hormone.
Its effect is present particularly in combination with other drugs of hypercortisolism of pituitary origin. The drug is also tested in the treatment of some patients with acromegaly and neuroendocrine tumors.
The main adverse event is a hyperglycemic effect.